Cell therapy process orders support Hexun's doubled revenue growth in April

Benefiting from an increase in customer orders for cell therapy process development, Hexun Biosicences reported a revenue of NT$18.22 million in April, achieving a remarkable year-on-year doubling of revenue, with a growth rate of 168%. From January to April, the revenue reached NT$37.78 million, representing a staggering year-on-year growth of 201%.